OptiMed Specialty Pharmacy to Distribute New Rheumatoid Arthriti - NBC12 - WWBT - Richmond, VA News On Your Side

OptiMed Specialty Pharmacy to Distribute New Rheumatoid Arthritis Drug

OptiMed will dispense the newly approved Kevzara (sarilumab) for the treatment of adults with moderate to severe rheumatoid arthritis.



Kalamazoo, Michigan - June 19, 2017 - (Newswire.com)

OptiMed Specialty Pharmacy will dispense the newly approved Kevzara (sarilumab) for the treatment of adults with moderate to severe rheumatoid arthritis who have had an inadequate response to other disease-modifying, anti-rheumatic drugs.

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which the immune system attacks the joint tissues, causing inflammation, pain, joint damage, and disability. Kevzara is an injectable interleukin-6 (IL-6) receptor antagonist that can be given alone or in combination with other anti-rheumatic medication. The agent is being co-marketed by Sanofi and Regeneron.

"We are excited to have another treatment option for patients suffering from this often debilitating disease," said Andy Reeves, RPh, OptiMed CEO. "RA can be a difficult condition to treat, and having newer therapies with varying mechanisms of action is proving helpful for our patients."

Specialty medications, such as Kevzara, may require extra monitoring to ensure safety and effectiveness. OptiMed Specialty Pharmacy works collaboratively with patients and prescribers to provide a comprehensive approach to patient care, ensuring that the medication is administered safely and appropriately for each patient. Patients are provided with customized education, access to financial assistance and ongoing monitoring and support. OptiMed holds dual specialty pharmacy accreditations from the Accreditation Commission for Health Care (ACHC) and URAC.

For more information, contact OptiMed at 877-232-2857 or visit www.optimedspecialtyrx.com.




Press Release Service by Newswire.com

Original Source: OptiMed Specialty Pharmacy to Distribute New Rheumatoid Arthritis Drug

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and have questions or removal reuqests please contact pressreleases@franklyinc.com

Powered by Frankly